TherapeuticsMD (NASDAQ: TXMD) reported Q3 EPS of ($0.11), $0.01 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $24.5 million versus the consensus estimate of $25.87 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.